As multiple myeloma and other blood cancers continue to challenge patients and clinicians alike, the market for Carvykti — a CAR-T cell therapy — is drawing growing scrutiny from investors and industry watchers seeking to understand where oncology treatment is headed. A new analysis from The Business Research Company maps out how that market has developed and where it is likely to go next.
The Business Research Company’s Carvykti Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035
The Carvykti market is attracting considerable attention as cancer therapies continue to advance. With multiple myeloma and other hematologic cancers presenting persistent difficulties, innovative treatments such as CAR-T cell therapies are becoming essential. This analysis examines historical growth, forecast trends, key drivers, and regional dynamics shaping the Carvykti market from 2026 to 2030.
Also worth a look: Splash Tents outfit veteran-owned Tex Vet Trees with 10×10 logo canopy for Central Texas events and Telemundo Intimacy Coordinator Constanza Espejo to Speak at IAFFM 2026.
Historical Growth and Projected Expansion of the Carvykti Market
Over the past several years, the Carvykti market expanded at a steady pace, shaped by a combination of forces. Gaps in traditional myeloma treatments fueled demand for new alternatives, while early successes with autologous cell therapies helped move the market forward. In addition, unmet needs among relapsed multiple myeloma patients, advances in gene modification technologies, and rising funding for oncology research all contributed significantly to growth. Looking ahead, the market is projected to advance further between 2026 and 2030. Supporting this growth are the increasing prevalence of multiple myeloma, broader regulatory approvals for CAR-T therapies, expanded manufacturing capacities, growing physician familiarity with CAR-T protocols, and the expansion of specialized oncology treatment centers.
Download a free sample of the carvykti market report:
https://thebusinessresearchcompany.com/sample_request?id=65473518&type=smp&name=Carvykti%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR
Emerging Trends Shaping the Carvykti Market’s Future
A major trend expected during the forecast period is the widening use of CAR-T cell therapies across a range of hematologic cancers beyond multiple myeloma. Personalized cancer treatments are gaining momentum as tailored approaches become more widespread. At the same time, attention is increasingly focused on therapies targeting BCMA, a key antigen expressed on malignant plasma cells. Investment in refining cell therapy production processes is on the rise, helping to expand supply and accessibility. Meanwhile, advanced oncology centers are becoming more centralized, delivering specialized care and easing the adoption of these innovative therapies.
How Carvykti Functions as a Targeted Cancer Therapy
Carvykti, whose generic name is ciltacabtagene autoleucel, is a CAR-T cell therapy intended for adults with relapsed or refractory multiple myeloma who have already received at least four prior lines of treatment. The therapy genetically engineers a patient’s own T cells so they can recognize and destroy plasma cells expressing the B-cell maturation antigen (BCMA) protein. This targeted approach helps improve outcomes for patients with few remaining options, offering a promising alternative in the fight against multiple myeloma.
View the full carvykti market report:
https://thebusinessresearchcompany.com/report/carvykti-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR
Key Factors Driving Growth in the Carvykti Market
The rising prevalence of cancer stands out as a crucial factor pushing the Carvykti market forward. Cancer — marked by the uncontrolled division and spread of abnormal cells — remains a leading cause of death worldwide. Its growing incidence is shaped by an aging population, lifestyle choices, environmental exposures, and improved detection methods. As a targeted CAR-T therapy, Carvykti offers a valuable option for patients with relapsed or refractory multiple myeloma, meeting an urgent clinical need. For example, in May 2024, the National Cancer Institute, part of the US National Institutes of Health, reported that the number of cancer survivors in the United States had reached approximately 18.1 million as of January 2022, with projections estimating an increase to 22.5 million by 2032. Such figures underscore the growing demand for effective therapies like Carvykti.
Regional Leadership and Market Outlook for Carvykti
In 2025, North America accounted for the largest share of the Carvykti market, a reflection of the region’s advanced healthcare infrastructure and regulatory environment. The Asia-Pacific region, however, is forecast to be the fastest-growing market segment in the coming years, propelled by rising awareness, improving healthcare systems, and expanding access to innovative therapies. The Carvykti market report covers key regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, offering a comprehensive view of global market trends and dynamics.
Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info
The Business Research Company – www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Why it matters: With cancer survivor numbers projected to climb from roughly 18.1 million in 2022 to 22.5 million by 2032, demand for targeted therapies like Carvykti is only expected to intensify. How quickly manufacturing scales and specialized treatment centers expand — particularly in the fast-growing Asia-Pacific region — will determine whether the market can keep pace with that need.
